Comparative Pharmacology
Head-to-head clinical analysis: PROSTAPHLIN versus SPECTROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROSTAPHLIN versus SPECTROBID.
PROSTAPHLIN vs SPECTROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaphlin (oxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1 and PBP3, leading to inhibition of transpeptidation and cell lysis. It is resistant to staphylococcal beta-lactamases.
Spectrobird (bacampicillin) is a prodrug of ampicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
250-500 mg IM or IV every 4-6 hours for moderate to severe infections. For oral use: 250-500 mg every 6 hours on empty stomach.
400 mg orally twice daily or 200 mg orally four times daily for 10-14 days. For acute exacerbations of chronic bronchitis: 400 mg orally twice daily for 10 days.
None Documented
None Documented
0.4-0.8 hours in adults with normal renal function; prolonged in renal impairment (up to 4-6 hours in anuria).
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged to 6-10 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (70-80% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: ~75-85% unchanged drug; fecal/biliary: ~15-25% as metabolites and unchanged drug.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic